PG-102

Phase 2Biologic

RRANI Therapeutics

PG-102 is one of 77 biologic programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusNot yet recruiting

Type 2 DiabetesNot yet recruiting

Type 2 Diabetes MellitusPhase 2

Not yet recruiting

Type 2 DiabetesPhase 2

Not yet recruiting

Competition

Competitive Landscape

165 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

NOVOLIN R

Novo Nordisk

Preclinical

5 2

PG-102

RRANI Therapeutics

Phase 2

2 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 4

Aurlumyn

BBTG International Inc.

Preclinical

1 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 7

GLP-1

RRigshospitalet, Denmark

Preclinical

2 8

Routine Treatment

GSK

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Type 2 Diabetes Mellitus

NCT07187856

Q2 2027

Phase 2Not yet recruiting

Type 2 Diabetes

NCT07677891

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

Active, not recruiting·PProGen. Co., Ltd.·Phase 2·NCT06712615·144 enrolled

A Randomized, Open-Label, Multicenter, Active-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Switching From Once-Weekly Dulaglutide to Once-Monthly PG-102(MG12) in Patients With Type 2 Diabetes Mellitus Receiving Stable Dulaglutide Therapy

Not yet recruiting·PProGen. Co., Ltd.·Phase 2·NCT07677891·60 enrolled

Obesity1 trial

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

Completed·PProGen. Co., Ltd.·Phase 1·NCT06309667·102 enrolled

Type 2 Diabetes Mellitus1 trial

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Not yet recruiting·PProGen. Co., Ltd.·Phase 2·NCT07187856·80 enrolled

Unspecified1 trial

An Early Phase Study of RT-114

Not yet recruiting·RRANI Therapeutics·Phase 1·NCT06891287·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PG-102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PG-102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PG-102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RANI Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: RRANI Therapeutics

PG-102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Type 2 Diabetes2 trials

Obesity1 trial

Type 2 Diabetes Mellitus1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News